TB-500 and Theoretical Cancer Concerns: What the Evidence Actually Shows

Is TB-500 the same thing as thymosin beta-4?

No, and the difference decides how much of the cancer discussion applies to what people actually inject.

Thymosin beta-4 is a 43-amino-acid protein, first isolated from calf thymus and found in blood, saliva, tears and wound fluid [1]. TB-500 is a synthetic fragment of it: residues 17 to 23, N-acetylated, molecular weight about 889 g/mol [1]. TB-500 is a common name rather than an official drug name, and FDA found several salts and derivatives, including different active moieties, sold under it [1].

The experiment that started the cancer question used the full-length protein, produced inside cells by gene transfer. FDA found no study of the fragment in people [1].

Where does the cancer concern come from?

Tumour growth in mice. Cha, Jeong and Kleinman, writing in the Journal of the National Cancer Institute in 2003, engineered mouse melanoma B16-F10 cells to overexpress full-length thymosin beta-4 and injected them into mice. Mean tumour size 20 days later was 21.7 mm with thymosin beta-4 versus 13.3 mm with control (P=.036). Two weeks after intravenous injection, mean metastatic lung nodules were 46.7 versus 10.9 (P<.001). Overexpression was associated with a 2.3-fold increase in cell migration and a 4.4-fold increase in the number of blood vessels in the tumours, with no effect on invasion, proliferation or matrix metalloproteinase activity [2].

That result came from engineered mouse melanoma cells making a protein they do not normally overproduce. It is not a study of injected TB-500, and it does not show what TB-500 does in people.

Actin binding. The nomination FDA reviewed describes the LKKTETQ stretch, which TB-500 contains, as the actin-binding site behind thymosin beta-4's wound-healing effects [1].

What is known about TB-500 itself?

FDA's July 2026 review found no nonclinical toxicity studies of TB-500, and no immunogenicity or aggregation studies [1].

In an in-vitro scratch-wound test, TB-500 at 50 microgram/mL did not induce wound closure in fibroblast cultures, although a shorter metabolite (N-acetylated LKKTE) did show activity [1]. FDA found no in-vivo animal study of TB-500 for wound healing [1].

Animal work suggests TB-500 given subcutaneously or intraperitoneally reaches the bloodstream and is broken down into smaller peptides; no animal studies using intramuscular injection were found [1].

What has been reported in people?

FDA's adverse-event database search through March 26, 2025 retrieved no TB-500 reports. FDA's food and supplement complaint system, covering January 1, 2004 to March 10, 2025, returned two cases involving a blended TB-500 and BPC-157 product, with no safety assessment, and FDA found no published case reports [1]. An empty reporting database is not proof of safety.

In its BPC-157 review, FDA describes a 40-year-old woman who injected a 'research purposes only' product containing 5 mg BPC-157 and 5 mg TB-500 subcutaneously twice daily and developed widespread skin hyperpigmentation and gum darkening within a week, which returned when she tried the product again two weeks later. Because the product held two peptides, FDA said it cannot tell whether either caused it [8].

What risk does FDA actually name?

FDA's stated concern for injectable TB-500 is immunogenicity, an immune reaction, potentially amplified by peptide aggregation and peptide-related impurities [1]. On its page for bulk substances that may raise significant safety risks, FDA lists 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500' in the 'nominated but withdrawn' table, and says it has not identified any human exposure data, lacks important safety information, and that injectable peptides may pose immunogenicity risk [9]. Removal from that category was not a finding that the substance is safe [9].

Is TB-500 approved, and what does that mean here?

TB-500 is not an FDA-approved drug. FDA's July 2026 review found no USP or National Formulary monograph for it, no FDA-approved drug containing it, no listing in the European or Japanese pharmacopeias, and no approved product in Canada, Australia, the UK, Belgium, Ireland, France, Norway, Germany, Spain or Italy, or authorised by the European Medicines Agency [1]. It appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians and is not on the list for outsourcing facilities [3][4][5].

In July 2026 the Pharmacy Compounding Advisory Committee voted in favour of adding TB-500 to FDA's list of bulk drug substances that can be used in compounding, against FDA staff's recommendation; that vote is advice only, and adding a substance takes formal rulemaking [12][13]. HHS's draft enforcement-discretion policy of October 2026 names TB-500 among six peptides and says HHS does not intend to take enforcement action against certain state-licensed pharmacies, federal facilities and licensed physicians if its conditions are met; the notice says the policy is not binding, and it is not an approval [13][14]. WADA's Prohibited List names 'Thymosin-beta4 and its derivatives e.g. TB-500' in S2.3, prohibited at all times, in and out of competition [6].